Does the media favor RIGL or BCRX?

In the previous week, Rigel Pharmaceuticals and Rigel Pharmaceuticals both had 8 articles in the media. BioCryst Pharmaceuticals' average media sentiment score of 1.33 beat Rigel Pharmaceuticals' score of 0.98 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZBIO or RIGL?

In the previous week, Rigel Pharmaceuticals had 4 more articles in the media than Zenas BioPharma. MarketBeat recorded 8 mentions for Rigel Pharmaceuticals and 4 mentions for Zenas BioPharma. Rigel Pharmaceuticals' average media sentiment score of 0.98 beat Zenas BioPharma's score of 0.64 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RIGL or INVA?

In the previous week, Innoviva had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 9 mentions for Innoviva and 8 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.98 beat Innoviva's score of 0.96 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MNKD or RIGL?

In the previous week, MannKind had 3 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 11 mentions for MannKind and 8 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.98 beat MannKind's score of 0.88 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NVAX or RIGL?

In the previous week, Novavax and Novavax both had 8 articles in the media. Rigel Pharmaceuticals' average media sentiment score of 0.98 beat Novavax's score of -0.01 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Rigel Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Live Earnings Conference Call: Rigel Pharmaceuticals' Q2 2026 earnings call is happening now. Listen live.

Rigel Pharmaceuticals (RIGL) Competitors

$38.70 +1.27 (+3.39%)

Closing price 04:00 PM Eastern

Extended Trading

$41.00 +2.30 (+5.94%)

As of 05:16 PM Eastern

Compare

RIGL vs. BCRX, ZBIO, INVA, MNKD, and NVAX

Should you buy Rigel Pharmaceuticals stock or one of its competitors? MarketBeat compares Rigel Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rigel Pharmaceuticals include BioCryst Pharmaceuticals (BCRX), Zenas BioPharma (ZBIO), Innoviva (INVA), MannKind (MNKD), and Novavax (NVAX). These companies are all part of the "biotechnology" industry.

How does Rigel Pharmaceuticals compare to BioCryst Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Rigel Pharmaceuticals has a net margin of 121.50% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Rigel Pharmaceuticals' return on equity of 47.99% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Rigel Pharmaceuticals has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.43	$367.02M	$18.72	2.07
BioCryst Pharmaceuticals	$874.84M	2.62	$263.86M	-$1.78	N/A

In the previous week, Rigel Pharmaceuticals and Rigel Pharmaceuticals both had 8 articles in the media. BioCryst Pharmaceuticals' average media sentiment score of 1.33 beat Rigel Pharmaceuticals' score of 0.98 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

Rigel Pharmaceuticals presently has a consensus target price of $54.50, indicating a potential upside of 40.83%. BioCryst Pharmaceuticals has a consensus target price of $20.80, indicating a potential upside of 130.60%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

BioCryst Pharmaceuticals beats Rigel Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Zenas BioPharma presently has a consensus target price of $44.29, indicating a potential upside of 40.95%. Rigel Pharmaceuticals has a consensus target price of $54.50, indicating a potential upside of 40.83%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Zenas BioPharma is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Rigel Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	198.35	-$377.74M	-$8.47	N/A
Rigel Pharmaceuticals	$294.28M	2.43	$367.02M	$18.72	2.07

In the previous week, Rigel Pharmaceuticals had 4 more articles in the media than Zenas BioPharma. MarketBeat recorded 8 mentions for Rigel Pharmaceuticals and 4 mentions for Zenas BioPharma. Rigel Pharmaceuticals' average media sentiment score of 0.98 beat Zenas BioPharma's score of 0.64 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zenas BioPharma has a beta of -1.03, indicating that its stock price is 203% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Rigel Pharmaceuticals has a net margin of 121.50% compared to Zenas BioPharma's net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 47.99% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

Summary

Rigel Pharmaceuticals beats Zenas BioPharma on 11 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Innoviva?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Innoviva (NASDAQ:INVA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

In the previous week, Innoviva had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 9 mentions for Innoviva and 8 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.98 beat Innoviva's score of 0.96 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 10.5% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Rigel Pharmaceuticals has higher earnings, but lower revenue than Innoviva. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.43	$367.02M	$18.72	2.07
Innoviva	$411.33M	3.74	$271.17M	$6.01	3.47

Rigel Pharmaceuticals has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Rigel Pharmaceuticals currently has a consensus price target of $54.50, indicating a potential upside of 40.83%. Innoviva has a consensus price target of $36.20, indicating a potential upside of 73.54%. Given Innoviva's stronger consensus rating and higher probable upside, analysts plainly believe Innoviva is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Innoviva	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Rigel Pharmaceuticals has a net margin of 121.50% compared to Innoviva's net margin of 119.89%. Rigel Pharmaceuticals' return on equity of 47.99% beat Innoviva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Innoviva	119.89%	33.33%	22.67%

Summary

Rigel Pharmaceuticals and Innoviva tied by winning 8 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to MannKind?

MannKind (NASDAQ:MNKD) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

49.6% of MannKind shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 2.6% of MannKind shares are owned by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MannKind has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

Rigel Pharmaceuticals has a net margin of 121.50% compared to MannKind's net margin of -6.63%. Rigel Pharmaceuticals' return on equity of 47.99% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

In the previous week, MannKind had 3 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 11 mentions for MannKind and 8 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.98 beat MannKind's score of 0.88 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind currently has a consensus price target of $9.34, indicating a potential upside of 135.95%. Rigel Pharmaceuticals has a consensus price target of $54.50, indicating a potential upside of 40.83%. Given MannKind's stronger consensus rating and higher probable upside, equities analysts plainly believe MannKind is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Rigel Pharmaceuticals has lower revenue, but higher earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.51	$5.86M	-$0.07	N/A
Rigel Pharmaceuticals	$294.28M	2.43	$367.02M	$18.72	2.07

Summary

Rigel Pharmaceuticals beats MannKind on 10 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Novavax?

Novavax (NASDAQ:NVAX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Novavax has a beta of 2.47, indicating that its stock price is 147% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

53.0% of Novavax shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Novavax has higher revenue and earnings than Rigel Pharmaceuticals. Novavax is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.12	$440.30M	-$0.58	N/A
Rigel Pharmaceuticals	$294.28M	2.43	$367.02M	$18.72	2.07

Rigel Pharmaceuticals has a net margin of 121.50% compared to Novavax's net margin of -14.73%. Rigel Pharmaceuticals' return on equity of 47.99% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

Novavax currently has a consensus price target of $13.00, suggesting a potential upside of 69.71%. Rigel Pharmaceuticals has a consensus price target of $54.50, suggesting a potential upside of 40.83%. Given Novavax's stronger consensus rating and higher possible upside, research analysts plainly believe Novavax is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Novavax and Novavax both had 8 articles in the media. Rigel Pharmaceuticals' average media sentiment score of 0.98 beat Novavax's score of -0.01 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rigel Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rigel Pharmaceuticals beats Novavax on 9 of the 16 factors compared between the two stocks.

Get Rigel Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RIGL vs. The Competition

Export

Metric	Rigel Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$715.95M	$3.56B	$6.80B	$13.02B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	2.07	7.35	279.73	25.56
Price / Sales	2.43	1,275.27	649.61	116.36
Price / Cash	5.46	44.80	28.64	34.82
Price / Book	1.79	17.09	11.12	6.36
Net Income	$367.02M	-$12.52M	$3.48B	$347.58M
7 Day Performance	0.52%	2.63%	2.67%	3.24%
1 Month Performance	-0.05%	-5.27%	-2.70%	-2.00%
1 Year Performance	70.71%	51.48%	64.43%	21.31%

Rigel Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RIGL Rigel Pharmaceuticals	4.3454 of 5 stars	$38.70 +3.4%	$54.50 +40.8%	+70.8%	$715.95M	$294.28M	2.07	160	News Coverage Earnings Report
BCRX BioCryst Pharmaceuticals	3.8193 of 5 stars	$9.58 +2.6%	$20.80 +117.1%	+10.8%	$2.37B	$874.84M	N/A	530	Positive News Upcoming Earnings
ZBIO Zenas BioPharma	3.4804 of 5 stars	$32.82 +8.0%	$44.29 +34.9%	+102.0%	$1.92B	$10M	N/A	N/A	News Coverage Upcoming Earnings
INVA Innoviva	3.2102 of 5 stars	$21.30 -0.7%	$36.20 +70.0%	+11.5%	$1.58B	$411.33M	3.54	100	Upcoming Earnings Analyst Downgrade
MNKD MannKind	3.217 of 5 stars	$3.95 -4.4%	$8.97 +127.1%	+1.3%	$1.28B	$348.97M	N/A	400	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RIGL) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. BCRX, ZBIO, INVA, MNKD, and NVAX

How does Rigel Pharmaceuticals compare to BioCryst Pharmaceuticals?

Summary

How does Rigel Pharmaceuticals compare to Zenas BioPharma?

Summary

How does Rigel Pharmaceuticals compare to Innoviva?

Summary

How does Rigel Pharmaceuticals compare to MannKind?

Summary

How does Rigel Pharmaceuticals compare to Novavax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. BCRX, ZBIO, INVA, MNKD, and NVAX

How does Rigel Pharmaceuticals compare to BioCryst Pharmaceuticals?

Is RIGL or BCRX more profitable?

Which has better valuation & earnings, RIGL or BCRX?

Does the media favor RIGL or BCRX?

Which has more risk and volatility, RIGL or BCRX?

Do analysts prefer RIGL or BCRX?

Do institutionals and insiders believe in RIGL or BCRX?

Summary

How does Rigel Pharmaceuticals compare to Zenas BioPharma?

Do analysts prefer ZBIO or RIGL?

Which has preferable earnings & valuation, ZBIO or RIGL?

Does the media favor ZBIO or RIGL?

Do insiders and institutionals believe in ZBIO or RIGL?

Which has more volatility and risk, ZBIO or RIGL?

Is ZBIO or RIGL more profitable?

Summary

How does Rigel Pharmaceuticals compare to Innoviva?

Does the media favor RIGL or INVA?

Do insiders & institutionals believe in RIGL or INVA?

Which has stronger valuation & earnings, RIGL or INVA?

Which has more risk & volatility, RIGL or INVA?

Do analysts rate RIGL or INVA?

Is RIGL or INVA more profitable?

Summary

How does Rigel Pharmaceuticals compare to MannKind?

Do insiders and institutionals have more ownership in MNKD or RIGL?

Which has more risk & volatility, MNKD or RIGL?

Is MNKD or RIGL more profitable?

Does the media prefer MNKD or RIGL?

Do analysts recommend MNKD or RIGL?

Which has better earnings and valuation, MNKD or RIGL?

Summary

How does Rigel Pharmaceuticals compare to Novavax?

Which has more volatility & risk, NVAX or RIGL?

Do institutionals & insiders hold more shares of NVAX or RIGL?

Which has preferable earnings & valuation, NVAX or RIGL?

Is NVAX or RIGL more profitable?

Do analysts recommend NVAX or RIGL?

Does the media refer more to NVAX or RIGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools